



Author index

Volume 23 (1994)

- Alberti, K.M.M., see Farrer, M. 23, 111
Aono, S., see Kida, K. 23, 187
- Barreira, V.I., see Reusens-Billen, B. 23, 85
Boehm, B.O., see Schifferdecker, E. 23, 17
Boisseau, M.R., see Seigneur, M. 23, 169
Borkenstein, M., see Schwingshandl, J. 23, 163
Bozzola, M., see Lorini, R. 23, 37
- Caporali, R., see d'Annunzio, G. 23, 63
Ciampi, A., see Schiffrin, A. 23, 95
Claverie, M., see Seigneur, M. 23, 169
Cortona, L., see Lorini, R. 23, 37
Cristallini, S., see Gregorio, F. 23, 43
Crockett, R., see Seigneur, M. 23, 169
- d'Annunzio, G., R. Caporali, R. Lorini, Anticardiolipin antibodies in children and adolescents with insulin-dependent diabetes mellitus 23, 63
d'Annunzio, G., see Lorini, R. 23, 37
de Clercq, L., see Reusens-Billen, B. 23, 85
Doi, K., see Kida, K. 23, 187
- Evans, K., see Farrer, M. 23, 111
- Fabris, S., see Proietto, J. 23, 127
Farrer, M., P.H. Winocour, K. Evans, H.W. Neil, M.F. Laker, P. Kesteven, K.M.M. Alberti, Simvastatin in non-insulin-dependent diabetes mellitus: Effect on serum lipids, lipoproteins and haemostatic measures 23, 111
Filipponi, P., see Gregorio, F. 23, 43
Forteleoni, G., see Meloni, T. 23, 59
Freyburger, G., see Seigneur, M. 23, 169
Fujioka, Y., see Takekawa, K. 23, 141
Fujisawa, T., see Takekawa, K. 23, 141
Fukuda, M., see Takekawa, K. 23, 141
Fumelli, P., see Gregorio, F. 23, 43
- Gin, H., see Seigneur, M. 23, 169
Gregorio, F., S. Cristallini, F. Santeusano, P. Filipponi, P. Fumelli, Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes? 23, 43
- Hanafusa, T., see Waguri, M. 23, 33
Hanotier, C.J., see Reusens-Billen, B. 23, 85
Harrison, L.C., see Proietto, J. 23, 127
Hasegawa, G., K. Nakano, Y. Tsutsumi, M. Kondo, Effects of aldehyde-modified proteins on mesangial cell-matrix interaction 23, 25
- Hendricks, L., see Schiffrin, A. 23, 95
Hibi, I., see Kida, K. 23, 187
Hoet, J.J., see Reusens-Billen, B. 23, 85
- Ikeda, M., see Kawamori, R. 23, 155
Ikeda, Y., see Kida, K. 23, 187
Ikegami, H., see Takekawa, K. 23, 141
Imagawa, A., see Waguri, M. 23, 33
Ishida, K., see Shima, K. 23, 147
Ishii, M., see Maruyama, T. 23, 77
Itoh, M., see Sudo, Y. 23, 69
Itoh, N., see Waguri, M. 23, 33
- Jinnouchi, T., see Kida, K. 23, 187
John, L., P. Mathews, R. Oommnen, Glomerular filtration rate in Indian non-insulin-dependent diabetics at various stages of albuminuria 23, 121
Joseph, T.A., see Ramachandran, A. 23, 55
- Kaino, Y., see Kida, K. 23, 187
Kalogeropoulou, K., see Migdalis, I.N. 23, 179
Kamada, T., see Kawamori, R. 23, 155
Kasatani, T., see Maruyama, T. 23, 77
Kasuga, A., see Maruyama, T. 23, 77
Kawaguchi, Y., see Takekawa, K. 23, 141
Kawamori, R., T. Morishima, M. Ikeda, M. Kubota, M. Kubota, M. Kishimoto, Y. Shiba, M. Matsuhisa, M. Kodama, T. Watarai, T. Kamada, Effect of strict metabolic control on glucose handling by the liver and peripheral tissues in non-insulin-dependent diabetes mellitus 23, 155
Kawata, S., see Waguri, M. 23, 33
Kesteven, P., see Farrer, M. 23, 111
Kishimoto, M., see Kawamori, R. 23, 155
Kitagawa, T., see Kida, K. 23, 187
Kobayashi, A., see Maruyama, T. 23, 77
Kobayashi, T., see Kida, K. 23, 187
Kodama, M., see Kawamori, R. 23, 155
Kondo, M., see Hasegawa, G. 23, 25
Kono, N., see Waguri, M. 23, 33
Koutoulidis, K., see Migdalis, I.N. 23, 179
Kubota, M., see Kawamori, R. 23, 155
Kubota, M., see Kawamori, R. 23, 155
Kuwayama, M., see Waguri, M. 23, 33
Kuzuya, H., see Kida, K. 23, 187
- Lacape, G., see Seigneur, M. 23, 169
Laker, M.F., see Farrer, M. 23, 111
Lardeau, D., see Seigneur, M. 23, 169
Le Moigne, F., see Seigneur, M. 23, 169

- Lewitt, M.S., Role of the insulin-like growth factors in the endocrine control of glucose homeostasis **23**, 3
- Lorini, R., A. Moretta, A. Valtorta, G. d'Annunzio, L. Cortona, L. Vitali, M. Bozzola, F. Severi, Cytotoxic activity in children with insulin-dependent diabetes mellitus **23**, 37
- Lorini, R., see d'Annunzio, G. **23**, 63
- Madhu, K., see Sridhar, G.R. **23**, 183
- Maruyama, T., A. Shimada, A. Kasuga, T. Kasatani, Y. Ozawa, M. Ishii, I. Takei, Y. Suzuki, A. Kobayashi, S. Takeda, K. Matsubara, T. Saruta, Analysis of MHC Class II antigens in Japanese IDDM by a novel HLA-typing method, hybridization protection assay **23**, 77
- Mathews, P., see John, L. **23**, 121
- Matsubara, K., see Maruyama, T. **23**, 77
- Matsuhisa, M., see Kawamori, R. **23**, 155
- Matsuura, N., see Kida, K. **23**, 187
- Matsuzawa, Y., see Waguri, M. **23**, 33
- Meloni, G.F., see Meloni, T. **23**, 59
- Meloni, T., A. Pacifico, G. Forteleoni, G.F. Meloni, HbA_{1c} levels in diabetic Sardinian patients with or without G6PD deficiency **23**, 59
- Migdalís, I.N., K. Kalogeropoulou, D. Zachariadis, K. Koutoulidis, M. Samartzis, Serum levels of Type III procollagen peptide and peripheral vascular disease in diabetic patients **23**, 179
- Mimura, G., see Kida, K. **23**, 187
- Miyagawa, J-i., see Waguri, M. **23**, 33
- Mizuno, A., see Shima, K. **23**, 147
- Moretta, A., see Lorini, R. **23**, 37
- Morishima, T., see Kawamori, R. **23**, 155
- Motala, A.A., M.A.K. Omar, Evaluation of WHO and NDDG criteria for impaired glucose tolerance **23**, 103
- Murakami, K., see Kida, K. **23**, 187
- Nakano, K., see Hasegawa, G. **23**, 25
- Neil, H.W., see Farrer, M. **23**, 111
- Nishimukai, H., see Kida, K. **23**, 187
- Ogihara, T., see Takekawa, K. **23**, 141
- Omar, M.A.K., see Motala, A.A. **23**, 103
- Oomnen, R., see John, L. **23**, 121
- Ozawa, Y., see Maruyama, T. **23**, 77
- Pacifico, A., see Meloni, T. **23**, 59
- Proietto, J., A.W. Thorburn, S. Fabris, L.C. Harrison, Effects of dexfenfluramine on glucose turnover in non-insulin-dependent diabetes mellitus **23**, 127
- Ramachandran, A., C. Snehalatha, T.A. Joseph, V. Vijay, M. Viswanathan, Height at onset of insulin-dependent diabetes in children in Southern India **23**, 55
- Remacle, C., see Reusens-Billen, B. **23**, 85
- Reusens-Billen, B., L. de Clercq, V.I. Barreira, C.J. Hanotier, C. Remacle, J.J. Hoet, Prevention of the cytotoxic effect of IL-1 by human lysozyme on isolated rat islets **23**, 85
- Rozen, R., see Schiffrin, A. **23**, 95
- Samartzis, M., see Migdalís, I.N. **23**, 179
- Sano, T., see Shima, K. **23**, 147
- Santeusano, F., see Gregorio, F. **23**, 43
- Saruta, T., see Maruyama, T. **23**, 77
- Schatz, H., see Schifferdecker, E. **23**, 17
- Schifferdecker, E., K. Schmidt, B.O. Boehm, H. Schatz, Long-term compliance of intensified insulin therapy **23**, 17
- Schiffrin, A., A. Ciampi, L. Hendricks, R. Rozen, G. Weitzner, Evidence for different clinical subtypes of Type 1 diabetes mellitus: a prospective study **23**, 95
- Schmidt, K., see Schifferdecker, E. **23**, 17
- Schwingshandl, J., M. Borkenstein, Effect of actual glycaemia on pupillary function in children with type 1 diabetes **23**, 163
- Seigneur, M., G. Freyburger, H. Gin, M. Claverie, D. Lardeau, G. Lacape, F. Le Moigne, R. Crockett, M.R. Boisseau, Serum fatty acid profiles in type I and type II diabetes: Metabolic alterations of fatty acids of the main serum lipids **23**, 169
- Severi, F., see Lorini, R. **23**, 37
- Shi, K., see Shima, K. **23**, 147
- Shiba, Y., see Kawamori, R. **23**, 155
- Shima, K., K. Shi, A. Mizuno, T. Sano, K. Ishida, S. Yoshimoto, Effects of difference in amount of exercise training on prevention of diabetes mellitus in the Otsuka-Long-Evans-Tokushima Fatty rats, a model of spontaneous non-insulin-dependent diabetes mellitus **23**, 147
- Shimada, A., see Maruyama, T. **23**, 77
- Snehalatha, C., see Ramachandran, A. **23**, 55
- Sridhar, G.R., K. Madhu, Prevalence of sleep disturbances in diabetes mellitus **23**, 183
- Sudo, Y., M. Itoh, Production of a monoclonal antibody 14A20 that reacts with a 220-kDa protein in the islet cells **23**, 69
- Sussman, K.E., Advances in clinical care — behavior vs. technology, a false dialectic **23**, 1
- Suzuki, Y., see Maruyama, T. **23**, 77
- Takeda, S., see Maruyama, T. **23**, 77
- Takei, I., see Maruyama, T. **23**, 77
- Takekawa, K., H. Ikegami, M. Fukuda, H. Ueda, Y. Kawaguchi, Y. Fujioka, T. Fujisawa, T. Ogihara, Early-onset type 2 (non-insulin-dependent) diabetes mellitus is associated with glucokinase locus, but not with adenosine deaminase locus, in the Japanese population **23**, 141
- Thorburn, A.W., see Proietto, J. **23**, 127
- Toyota, T., see Kida, K. **23**, 187
- Tsutsumi, Y., see Hasegawa, G. **23**, 25
- Tuchida, I., see Kida, K. **23**, 187
- Ueda, H., see Takekawa, K. **23**, 141
- Valtorta, A., see Lorini, R. **23**, 37
- Vijay, V., see Ramachandran, A. **23**, 55
- Viswanathan, M., see Ramachandran, A. **23**, 55
- Vitali, L., see Lorini, R. **23**, 37
- Waguri, M., T. Hanafusa, N. Itoh, A. Imagawa, J-i. Miyagawa, S. Kawata, N. Kono, M. Kuwajima, Y. Matsuzawa, Occurrence of IDDM during interferon therapy for chronic viral hepatitis **23**, 33
- Wardle, E.N., Vascular permeability in diabetics and implications for therapy **23**, 135
- Watarai, T., see Kawamori, R. **23**, 155
- Weitzner, G., see Schiffrin, A. **23**, 95
- Winocour, P.H., see Farrer, M. **23**, 111
- Yoshimoto, S., see Shima, K. **23**, 147
- Zachariadis, D., see Migdalís, I.N. **23**, 179



Subject index

Volume 23 (1994)

Abdominal fat; NIDDM; Exercise; Sedentary; Insulin resistance 23, 147

Actual glycaemia; Autonomic function; Diabetes; Children 23, 163

Adenosine deaminase; Type 2 (non-insulin-dependent) diabetes mellitus; Glucokinase; Microsatellite; Genetic susceptibility 23, 141

Albuminuria; Non-insulin-dependent diabetes; Glomerular filtration rate; Hypertension 23, 121

Antioxidants; Vascular permeability in diabetes; Lipid peroxides; Probucol; Oleic acid; Heparan sulphates 23, 135

Autoantibodies; Insulin-dependent diabetes mellitus (IDDM); Islet cell antibodies (ICA); HLA 23, 187

Autonomic function; Diabetes; Actual glycaemia; Children 23, 163

Blood glucose control; 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor; Non-insulin-dependent diabetes; Lipids; Lipoprotein composition; Haemostasis; Insulinaemia 23, 111

Bone metabolism; NIDDM; Osteopenia; Osteoporosis; PTH 23, 43

C-peptide; Islet cell antibodies; Type 1 diabetes; HLA-DR clinical subtype; HLA-DQ clinical subtype 23, 95

Cell-matrix interaction; Mesangial cell; Glycolaldehyde-modified protein; Diabetic nephropathy 23, 25

Children; Autonomic function; Diabetes; Actual glycaemia 23, 163

Complication; Insomnia; Difficulty in initiating sleep 23, 183

Continuous subcutaneous infusion; Intensified insulin therapy;

Insulin-dependent diabetes mellitus; Normoglycemia; Diabetes complications 23, 17

Counterregulation; Insulin-like growth factor; Insulin-like growth factor-binding protein; Glucose homeostasis 23, 3

Dexfenfluramine; Hepatic glucose production; Glucose turnover; Non-insulin-dependent diabetes mellitus 23, 127

Diabetes; Autonomic function; Actual glycaemia; Children 23, 163

Diabetes; Fatty acids; Lipids; Serum 23, 169

Diabetes complications; Intensified insulin therapy; Insulin-dependent diabetes mellitus; Continuous subcutaneous infusion; Normoglycemia 23, 17

Diabetes in children; IDDM; Height at onset of diabetes 23, 55

Diabetes prevention; Human lysozyme; Islet of Langerhans; IL-1; INF- γ ; Rat 23, 85

Diabetic nephropathy; Mesangial cell; Cell-matrix interaction; Glycolaldehyde-modified protein 23, 25

Diagnostic criteria; Impaired glucose tolerance 23, 103

Difficulty in initiating sleep; Insomnia; Complication 23, 183

Exercise; NIDDM; Sedentary; Insulin resistance; Abdominal fat 23, 147

Fatty acids; Diabetes; Lipids; Serum 23, 169

Genetic susceptibility; Type 2 (non-insulin-dependent) diabetes mellitus; Glucokinase; Adenosine deaminase; Microsatellite 23, 141

Glomerular filtration rate; Non-insulin-dependent diabetes; Albuminuria; Hypertension 23, 121

Glucokinase; Type 2 (non-insulin-dependent) diabetes mellitus; Adenosine deaminase; Microsatellite; Genetic susceptibility 23, 141

Glucose clamp; Insulin resistance; Non-insulin-dependent diabetes mellitus; Hepatic glucose uptake; Intensified insulin therapy 23, 155

Glucose homeostasis; Insulin-like growth factor; Insulin-like growth factor-binding protein; Counterregulation 23, 3

Glucose turnover; Dexfenfluramine; Hepatic glucose production; Non-insulin-dependent diabetes mellitus 23, 127

Glycolaldehyde-modified protein; Mesangial cell; Cell-matrix interaction; Diabetic nephropathy 23, 25

Haemostasis; 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor; Non-insulin-dependent diabetes; Lipids; Lipoprotein composition; Blood glucose control; Insulinaemia 23, 111

Height at onset of diabetes; IDDM; Diabetes in children 23, 55

Heparan sulphates; Vascular permeability in diabetes; Lipid peroxides; Antioxidants; Probucol; Oleic acid 23, 135

Hepatic glucose production; Dexfenfluramine; Glucose turnover; Non-insulin-dependent diabetes mellitus 23, 127

Hepatic glucose uptake; Glucose clamp; Insulin resistance; Non-insulin-dependent diabetes mellitus; Intensified insulin therapy 23, 155

HLA; IDDM; Slowly progressive IDDM; Hybridization protection assay 23, 77

HLA; Insulin-dependent diabetes mellitus (IDDM); Islet cell antibodies (ICA); Autoantibodies 23, 187

HLA-DQ clinical subtype; Islet cell antibodies; Type 1 diabetes; C-peptide; HLA-DR clinical subtype 23, 95

HLA-DR clinical subtype; Islet cell antibodies; Type 1 diabetes; C-peptide; HLA-DQ clinical subtype 23, 95

Human lysozyme; Islet of Langerhans; IL-1; INF- γ ; Rat; Diabetes prevention 23, 85

Hybridization protection assay; IDDM; Slowly progressive IDDM; HLA 23, 77

3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor; Non-insulin-dependent diabetes; Lipids; Lipoprotein composition; Haemostasis; Blood glucose control; Insulinaemia 23, 111

Hypertension; Non-insulin-dependent diabetes; Albuminuria; Glomerular filtration rate 23, 121

IDDM; Diabetes in children; Height at onset of diabetes 23, 55

IDDM; Interferon; Viral hepatitis; Islet cell antibody 23, 33

IDDM; Slowly progressive IDDM; HLA; Hybridization protection assay 23, 77

IL-1; Human lysozyme; Islet of Langerhans; INF- γ ; Rat; Diabetes prevention 23, 85

Immunocytochemistry; Islet cell cytoplasmic antibody; Multireactivity; 220-kDa protein 23, 69

Impaired glucose tolerance; Diagnostic criteria 23, 103

INF- γ ; Human lysozyme; Islet of Langerhans; IL-1; Rat; Diabetes prevention 23, 85

Insomnia; Difficulty in initiating sleep; Complication 23, 183

Insulin resistance; Glucose clamp; Non-insulin-dependent diabetes mellitus; Hepatic glucose uptake; Intensified insulin therapy 23, 155

Insulin resistance; NIDDM; Exercise; Sedentary; Abdominal fat 23, 147

Insulin-dependent diabetes mellitus; Intensified insulin therapy; Continuous subcutaneous infusion; Normoglycemia; Diabetes complications 23, 17

Insulin-dependent diabetes mellitus; Natural killer cells; Lymphokine-activated killer cells 23, 37

Insulin-dependent diabetes mellitus (IDDM); Islet cell antibodies (ICA); Autoantibodies; HLA 23, 187

Insulin-like growth factor; Insulin-like growth factor-binding protein; Glucose homeostasis; Counterregulation 23, 3

Insulin-like growth factor-binding protein; Insulin-like growth factor; Glucose homeostasis; Counterregulation 23, 3

Insulinaemia; 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor; Non-insulin-dependent diabetes; Lipids; Lipoprotein composition; Haemostasis; Blood glucose control 23, 111

Intensified insulin therapy; Glucose clamp; Insulin resistance; Non-insulin-dependent diabetes mellitus; Hepatic glucose uptake 23, 155

Intensified insulin therapy; Insulin-dependent diabetes mellitus; Continuous subcutaneous infusion; Normoglycemia; Diabetes complications 23, 17

Interferon; IDDM; Viral hepatitis; Islet cell antibody 23, 33

Islet cell antibodies (ICA); Insulin-dependent diabetes mellitus (IDDM); Autoantibodies; HLA 23, 187

Islet cell antibodies; Type 1 diabetes; C-peptide; HLA-DR clinical subtype; HLA-DQ clinical subtype 23, 95

Islet cell antibody; IDDM; Interferon; Viral hepatitis 23, 33

Islet cell cytoplasmic antibody; Immunocytochemistry; Multi-reactivity; 220-kDa protein 23, 69

Islet of Langerhans; Human lysozyme; IL-1; INF- γ ; Rat; Diabetes prevention 23, 85

220-kDa protein; Islet cell cytoplasmic antibody; Immunocytochemistry; Multireactivity 23, 69

Lipid peroxides; Vascular permeability in diabetes; Antioxidants; Probucol; Oleic acid; Heparan sulphates 23, 135

Lipids; 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor; Non-insulin-dependent diabetes; Lipoprotein composition; Haemostasis; Blood glucose control; Insulinaemia 23, 111

Lipids; Diabetes; Fatty acids; Serum 23, 169

Lipoprotein composition; 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor; Non-insulin-dependent diabetes; Lipids; Haemostasis; Blood glucose control; Insulinaemia 23, 111

Lymphokine-activated killer cells; Insulin-dependent diabetes mellitus; Natural killer cells 23, 37

Macroangiopathy; Type III procollagen peptide; Type 2 diabetes 23, 179

Mesangial cell; Cell-matrix interaction; Glycolaldehyde-modified protein; Diabetic nephropathy 23, 25

Microsatellite; Type 2 (non-insulin-dependent) diabetes mellitus; Glucokinase; Adenosine deaminase; Genetic susceptibility 23, 141

Multireactivity; Islet cell cytoplasmic antibody; Immunocytochemistry; 220-kDa protein 23, 69

Natural killer cells; Insulin-dependent diabetes mellitus; Lymphokine-activated killer cells 23, 37

NIDDM; Exercise; Sedentary; Insulin resistance; Abdominal fat 23, 147

NIDDM; Osteopenia; Osteoporosis; PTH; Bone metabolism 23, 43

Non-insulin-dependent diabetes; 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor; Lipids; Lipoprotein composition; Haemostasis; Blood glucose control; Insulinaemia 23, 111

Non-insulin-dependent diabetes; Albuminuria; Glomerular filtration rate; Hypertension 23, 121

Non-insulin-dependent diabetes mellitus; Dexfenfluramine; Hepatic glucose production; Glucose turnover 23, 127

Non-insulin-dependent diabetes mellitus; Glucose clamp; Insulin resistance; Hepatic glucose uptake; Intensified insulin therapy 23, 155

Normoglycemia; Intensified insulin therapy; Insulin-dependent diabetes mellitus; Continuous subcutaneous infusion; Diabetes complications 23, 17

Oleic acid; Vascular permeability in diabetes; Lipid peroxides; Antioxidants; Probucol; Heparan sulphates 23, 135

Osteopenia; NIDDM; Osteoporosis; PTH; Bone metabolism 23, 43

Osteoporosis; NIDDM; Osteopenia; PTH; Bone metabolism 23, 43

Probucol; Vascular permeability in diabetes; Lipid peroxides; Antioxidants; Oleic acid; Heparan sulphates 23, 135

PTH; NIDDM; Osteopenia; Osteoporosis; Bone metabolism 23, 43

Rat; Human lysozyme; Islet of Langerhans; IL-1; INF- γ ; Diabetes prevention 23, 85

Sedentary; NIDDM; Exercise; Insulin resistance; Abdominal fat 23, 147

Serum; Diabetes; Fatty acids; Lipids 23, 169

Slowly progressive IDDM; IDDM; HLA; Hybridization protection assay 23, 77

Type 1 diabetes; Islet cell antibodies; C-peptide; HLA-DR clinical subtype; HLA-DQ clinical subtype 23, 95

Type 2 (non-insulin-dependent) diabetes mellitus; Glucokinase; Adenosine deaminase; Microsatellite; Genetic susceptibility 23, 141

Type 2 diabetes; Type III procollagen peptide; Macroangiopathy 23, 179

Type III procollagen peptide; Macroangiopathy; Type 2 diabetes 23, 179

Vascular permeability in diabetes; Lipid peroxides; Antioxidants; Probucol; Oleic acid; Heparan sulphates 23, 135

Viral hepatitis; IDDM; Interferon; Islet cell antibody 23, 33

